Given Evoke Pharma's history of beating EPS estimates but experiencing share price declines, and considering the significant 80.42% decrease in its stock price over the past year, it's likely that the upcoming earnings report could result in a negative short-term impact on EVOK's stock price. The anticipation of the earnings report, coupled with the company's guidance for future quarters, will be critical for investors. However, the consistent pattern of post-earnings share price drops and overall negative sentiment among long-term shareholders suggest a cautious outlook.